Search Within

Alexander Edward Drilon

  1. "Body Imaging Service"
Formats
  1. Journal Article (28)
  2. Meeting Abstract (16)
Groups
  1. Body Imaging Service (44)
  2. Department of Medicine (44)
  3. Radiology, Department of (44)
  4. Solid Tumor Oncology Division (44)
  5. Thoracic Oncology (44)
  6. Department of Pathology and Laboratory Medicine (37)

More Groups

People
  1. Mark Kris (27)
  2. Charles Rudin (22)
  3. Marc Ladanyi (21)
  4. Michelle Ginsberg (21)
  5. Andrew Plodkowski (19)
  6. Bob Li (18)

More People

Years
  1. 2024 (4)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (1)
  6. 2019 (6)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Cancer Discovery (5)
  3. JCO Precision Oncology (5)
  4. Annals of Oncology (4)
  5. Journal of Thoracic Oncology (4)
  6. Clinical Cancer Research (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. American Association for Cancer Research (9)
  3. Elsevier Inc. (6)
  4. Oxford University Press (4)
  5. Elsevier Ireland Ltd. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (44)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
    Journal Article

    Jordan, E. J.; Kim, H. R.; Arcila, M. E.; Barron, D.; Chakravarty, D.; Gao, J. J.; Chang, M. T.; Ni, A.; Kundra, R.; Jonsson, P.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Journal Article

    Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
    Journal Article

    Drilon, A.; Bergagnini, I.; Delasos, L.; Sabari, J.; Woo, K. M.; Plodkowski, A.; Wang, L.; Hellmann, M. D.; Joubert, P.; Sima, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Response to MET inhibitors in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P.; Drilon, A.; Yu, H.; Rekhtman, N.; Borsu, L.; Ginsberg, M.; Berger, M.; Ladanyi, M.; Rudin, C. M.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Journal Article

    Plodkowski, A. J.; Drilon, A.; Halpenny, D. F.; O'Driscoll, D.; Blair, D.; Litvak, A. M.; Zheng, J.; Moskowitz, C. S.; Ginsberg, M. S.
    Lung Cancer (2015)

    Fulltext@MSK | Save
  • Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas
    Journal Article

    Eng, J.; Woo, K. M.; Sima, C. S.; Plodkowski, A.; Hellmann, M. D.; Chaft, J. E.; Kris, M. G.; Arcila, M. E.; Ladanyi, M.; Drilon, A.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A. E.; Sima, C. S.; Somwar, R.; Smith, R.; Ginsberg, M. S.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; Kris, M. G.; Rizvi, N. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save